Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

2022358 citationsJournal Articlehybrid Open Access

Authors

Thierry André · Inserm

David Tougeron · Université de Poitiers

Guillaume Piessen · Centre National de la Recherche Scientifique

Christelle de la Fouchardière

Christophe Louvet · Institute Mutualiste Montsouris

Antoine Adenis · Inserm

Marine Jary · Centre Hospitalier Universitaire de Besançon

Abstract

Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.

Topics & Keywords

Gastric Cancer Management and Outcomes Gastrointestinal Tumor Research and Treatment Esophageal Cancer Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 2, pp. 255-265

DOI: 10.1200/jco.22.00686

Field-Weighted Citation Impact: 47.96